Prof. PeptideProf. Peptide

KLOW

Skin Health & Anti-AgingResearch-GradeCombination Blend

Last reviewed: September 20, 2026

Quick Facts

What it is
A fixed-dose combination of BPC-157, TB-500, GHK-Cu, and KPV in a single injection — studied for tissue repair, skin remodeling, and anti-inflammatory/gut effects.
How it's taken
Subcutaneous injection, once daily (commonly at bedtime)
Half-life
Not established for the blend — varies by component
Typical research dose
0.1 mL (10 units) once daily from an 80 mg vial — ~2.5 mg GHK-Cu + 0.5 mg each BPC-157/TB-500/KPV — in 8–12 week cycles
Research status
Not FDA-approved — research use only.
On this page
  1. 1.What is KLOW?
  2. 2.How does KLOW work?
  3. 3.What is KLOW used for?
  4. 4.How long does KLOW take to work?
  5. 5.How is KLOW dosed?
  6. 6.How is KLOW administered?
  7. 7.What does KLOW stack well with?
  8. 8.What are the side effects of KLOW?
  9. 9.Does KLOW interact with other drugs?
  10. 10.How should KLOW be stored?
  11. 11.What are the limitations of KLOW research?
  12. 12.KLOW FAQ
  13. 13.References
  14. 14.Published Studies

What is KLOW?

KLOW is a research-grade 4-component peptide blend combining BPC-157, TB-500, GHK-Cu, and KPV in a single injection. It extends the 3-component GLOW blend by adding KPV, a tripeptide derived from α-melanocyte-stimulating hormone (α-MSH) that suppresses NF-κB-mediated inflammation. The result is the most comprehensive of the BPC/TB-based recovery blends: tissue repair from BPC-157 + TB-500, skin remodeling from GHK-Cu, and inflammation control from KPV — on a calmer tissue background.

Reported benefits:

  • Soft-tissue injury work with persistent inflammatory component (tendon, ligament, muscle)
  • Post-procedure aesthetic recovery (microneedling, laser, surgery)
  • Reactive or chronically inflamed skin where pure GLOW would aggravate
  • Comprehensive collagen + extracellular matrix remodeling on top of inflammation suppression
  • Gut and mucosal barrier work (mechanistic — based on KPV and BPC-157 component literature)
  • Single-injection convenience vs four separate peptide protocols

Common research dose: 0.1 mL (10 units on a U-100 insulin syringe) once daily subcutaneously from an 80 mg vial reconstituted with 2 mL bacteriostatic water — delivering ~2.5 mg GHK-Cu + 0.5 mg of each of BPC-157, TB-500, and KPV per dose. Standard cycle 8–12 weeks active, 4-week break.

Where to buy: KLOW is sold by specialty research peptide vendors as a compounded blend, typically as an 80 mg vial. None of the four components are FDA-approved as injectables. See Verified Discount Codes for current options.

Amino Club40% off

ILS Laboratories · batch COAs

Shop Amino Club
Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos
Ameano Peptides10% off

Certificates checked at Janoshik

Shop Ameano Peptides
Compare prices across 37 vendors

Also stocking KLOW

GenPeptide, Ion Peptide, NovaForge Labs, Oasis Labs — each carries a current price row for this compound.

Compare all 37 vendors stocking KLOW

How does KLOW work?

KLOW combines four research peptides that each target a different stage of tissue repair. BPC-157 and TB-500 act like the demolition and framing crew — they rebuild blood vessels and move repair cells into position. GHK-Cu is the finishing crew, laying down new collagen and signaling skin and connective tissue to remodel. KPV (a tripeptide from the same family as α-MSH, the hormone behind pigmentation) acts as a fire marshal — it keeps inflammation from drowning out the rebuild signals.

  1. BPC-157 — Vascular Repair [2]. BPC-157 (Body Protection Compound) activates the nitric oxide / VEGFR2 / FAK-paxillin axis to drive angiogenesis and endothelial protection. It rebuilds the blood supply that healing tissue needs, and stabilizes vascular networks at injury sites.
  2. TB-500 — Cellular Migration [3]. TB-500, the active fragment of thymosin β4, sequesters G-actin to enable cytoskeletal remodeling. The functional effect is rapid migration of fibroblasts and endothelial progenitor cells to injury sites, plus the anti-fibrotic Ac-SDKP fragment that biases healing toward functional tissue rather than scar.
  3. GHK-Cu — Collagen and Gene Modulation [1]. GHK-Cu (copper tripeptide) shuttles copper into cells. A review by Pickart and Margolina reports, from Connectivity Map data in cancer cell lines, that GHK shifts expression of over 4,000 human genes associated with skin remodeling, antioxidant defense, and stem-cell support. Its strongest signals are in dermal collagen synthesis, lysyl-oxidase cross-linking, and clearance of damaged extracellular matrix.
  4. KPV — Inflammation Control [4][5]. KPV (lysine–proline–valine) is the C-terminal tripeptide of α-MSH. It enters cells via the PepT1 nutrient transporter and inhibits NF-κB nuclear translocation — blocking transcription of TNF-α, IL-6, IL-1β, and adhesion molecules. In mouse colitis, KPV's effects were at least partly independent of MC1R signaling (Kannengiesser 2008); whether it binds melanocortin receptors has not been shown, and no human study has measured pigmentation, appetite, or immune effects.
  5. Composite effect — Repair on a calm background. The three regenerative components (BPC-157, TB-500, GHK-Cu) act on a tissue environment that KPV is actively de-inflaming. In principle this allows the rebuilding signals to reach their cellular targets without being attenuated by chronic NF-κB activation. The synergy is mechanistic — there is no controlled trial of the four-component blend. The one directly relevant combination data point that does exist is narrower and less favorable than the mechanistic story: a 2026 rat study testing BPC-157 and TB-500 together (two of KLOW's four components) found the combination produced no additional benefit over either peptide alone [7], and a small human case series of combined BPC-157 + TB-500 knee injections showed a lower response rate than BPC-157 alone [8].

What is KLOW used for?

Researchers use KLOW where the goal is broad tissue and skin recovery on top of a controlled inflammatory environment. Where Wolverine Stack is for pure injury work and GLOW adds skin quality, KLOW adds the inflammation-control layer that's useful when the tissue or skin in question is reactive — irritated, post-procedural, autoimmune-adjacent, or chronically inflamed. None of the research below is from controlled trials of the KLOW blend itself; it comes from each component's independent literature.

  1. Reactive Skin and Post-Procedure Recovery — Inflammation control from KPV plus collagen remodeling from GHK-Cu plus angiogenic support from BPC-157 makes KLOW the most-cited blend for post-microneedling, post-laser, and post-surgical aesthetic recovery use cases in research-community discussions.
  2. Soft-Tissue Injury With Inflammatory Component — Tendon, ligament, or muscle injuries with persistent inflammation. BPC-157 and TB-500 supply the repair signals; KPV dampens NF-κB to prevent inflammatory drag on healing.
  3. Gut and Mucosal Barrier — KPV has independent preclinical evidence in inflammatory bowel models, where it suppresses NF-κB and protects mucosal barriers. BPC-157 has been studied separately for gastrointestinal protection. The combined application is mechanistically rational but not directly studied as KLOW.
  4. Chronic Inflammatory Skin Conditions — Atopic and irritant dermatitis models have shown anti-inflammatory effects from KPV alone. The addition of GHK-Cu's barrier-remodeling activity is the rationale for KLOW use in such applications.
  5. Hair Follicle Stimulation — GHK-Cu's dominant contribution; BPC-157's angiogenic effect on follicular blood supply supports the same outcome. Effects are sometimes reported 60–90 days into a protocol, though no trial or label has been identified establishing this timeframe.

How long does KLOW take to work?

KLOW effects build progressively across an 8–12 week cycle. Visible improvements in skin texture and tone usually appear by week 3–4, similar to topical retinoids on a faster timeline. Fine-line softening and inflammatory-skin calming follow at weeks 4–6. Deeper structural changes — scar remodeling, sustained tendon or ligament repair, collagen-driven firmness — accumulate through weeks 8–12.

Tissue repair signals from BPC-157 and TB-500 act fast: angiogenesis markers can shift in days. KPV's anti-inflammatory effect is similarly rapid — NF-κB inhibition begins after the first dose. GHK-Cu's gene-modulating effects accumulate more slowly because they require ongoing transcription cycles, which is why structural skin and connective-tissue improvements typically lag the inflammation calming by several weeks. A standard protocol runs 8–12 weeks active with a 4-week break, then optional re-cycle.

How is KLOW dosed?

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

No trial has tested the four-component KLOW combination, and no dose exists for it as a blend. The figures below are split into what the cited literature actually administered for each component (including, for two of the four components, one small combined-administration data set — see below), and separately, community/vendor-reported vial practice, labelled as such and never presented as a finding.

What the cited literature administered

  • BPC-157 + TB-500 — the one real combined-administration data set [7][8]. Biçer et al. (Jt Dis Relat Surg, 2026, PMID 42542926) directly tested BPC-157 (10 µg/kg/day) and TB-500 (60 µg/kg/day) together, intraperitoneally, in a rat Achilles-tendon-repair model — the only cited literature that actually gave two KLOW components, under the TB-500 name specifically, in combination. Result: the combined group did not show additional benefit over either peptide alone; TB-500 alone produced the strongest biomechanical and histological improvement of the four arms. A separate paper, Lee & Padgett (Altern Ther Health Med, 2021, PMID 34324435), reported a retrospective 17-patient chart review of intra-articular knee injections in which 4 patients received combined BPC-157 + a second peptide the paper names only as thymosin beta-4 (TB4) — never TB-500 — with 75% reporting improvement versus 91.6% of the 12 patients who received BPC-157 alone. Because that paper does not name TB-500, it is reported here as related human context for a different but similar combination, not as human evidence for KLOW's own TB-500 component. Neither study used KLOW's route (subcutaneous) or dose units (flat mg), and neither included GHK-Cu or KPV. This is Animal Model evidence for a 2-of-4-component combination under the TB-500 name specifically, not for KLOW.
  • BPC-157 alone. No human trial has established a subcutaneous BPC-157 dose. The human data is three small, uncontrolled papers by the same lead author: the Lee & Padgett knee series above (intra-articular), a 12-patient interstitial cystitis series (bladder injections during cystoscopy), and a 2-person IV safety study. None used the subcutaneous route KLOW uses. See the BPC-157 profile for the full literature-vs-community breakdown.
  • TB-500 alone. No human study of TB-500 was found; the Lee & Padgett combination arm used full-length thymosin beta-4, not TB-500. The only dose-finding evidence is the Biçer animal study. See the TB-500 profile.
  • GHK-Cu. No human study of injected GHK-Cu was found — every study located for the component page tested it topically. The injectable dose used in KLOW has no literature basis at all; it is vendor/community convention only. See the GHK-Cu profile.
  • KPV. No human trial of KPV has established a dose. The cited animal colitis literature (Kannengiesser et al. 2008) demonstrates efficacy in mice, but the specific doses administered sit behind a paywalled methods section Prof. Peptide could not independently verify. See the KPV profile.

Adverse events reported in the same studies

Biçer et al. 2026 reported no animal deaths, postoperative infections, wound complications, tendon reruptures, or protocol-related exclusions in any of the four treatment groups (control, BPC-157, TB-500, combined) over the 4-week study. Lee & Padgett 2021 reported no serious adverse events across the 17-patient chart review, including its BPC-157 + thymosin beta-4 (not TB-500) combination subgroup. Kannengiesser et al. 2008 reported no adverse findings in their own results for the KPV-treated mice. GHK-Cu's topical human trial (see the GHK-Cu profile) has no bearing on the injectable route KLOW uses, so it is not cited here as injectable safety evidence.

Community/vendor-reported practice (unverified)

The 80 mg KLOW vial is the dominant SKU across specialty peptide vendors, at a fixed 50 mg GHK-Cu (62.5%) + 10 mg BPC-157 (12.5%) + 10 mg TB-500 (12.5%) + 10 mg KPV (12.5%) ratio — a vendor formulation choice, not derived from any of the studies above. Reported practice is to reconstitute with 2 mL bacteriostatic water and inject 0.1 mL (10 units on a U-100 insulin syringe) once daily subcutaneously, delivering ~2.5 mg GHK-Cu + 0.5 mg each of BPC-157, TB-500, and KPV per dose; some skincare-focused protocols instead use 2.5 mL BAC water for a ~2 mg GHK-Cu-anchored dose. A commonly reported cycle is 8–12 weeks active, then 4–8 weeks off. None of these figures come from a study of any KLOW component, let alone the combination — and the one real combined-administration evidence available (BPC-157 + TB-500, above) found no additive benefit from combining, which cuts against the vendor rationale for combining components in the first place.

Ratio variants. Some vendors offer different SKUs — 40 mg, 50 mg, or 100 mg total — with the same 5:1:1:1 component ratio. Verify the per-component breakdown on the vendor's Certificate of Analysis before scaling a protocol.

KLOW is not FDA-approved. Dosing is community/vendor-derived — there are no approved retail dosing standards for the blend, and no trial has tested the four-component combination.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

How is KLOW administered?

KLOW is administered by subcutaneous injection, the same route used for insulin and most research peptides — under the skin, not into muscle. A small insulin syringe makes this straightforward. The blend is once-daily, typically at bedtime, with site rotation to spread injection-site reactions across abdomen, thigh, and upper arm.

  1. Route. Subcutaneous injection. Common sites are the abdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms.
  2. Time of day. Bedtime is the standard default — gives the peptides an undisturbed window during early-night tissue repair cycles. Any consistent time works.
  3. With or without food. Either is fine. KLOW components do not interact with food absorption.
  4. Site rotation. Reported practice alternates sites each injection, staying at least 1 inch from previous injection sites — mild injection-site reactions are the most commonly reported side effect.
  5. Missed dose. Reported practice resumes on the next scheduled day. The convention is not to double-dose to compensate for a missed daily injection.
  6. Reconstitution. Use bacteriostatic water for injection (BAC water) at the volume specified by the dosing calculator. Swirl gently — do not shake — to avoid damaging the peptides.
  7. Local injection for soft-tissue work. For tendon, ligament, or post-procedure recovery applications, researchers often inject within 1–2 inches of the affected area rather than at a distant rotation site.

What does KLOW stack well with?

KLOW is designed to be a standalone blend — it already contains four peptides covering tissue repair, skin remodeling, and inflammation control. Most useful additions are non-peptide (resistance training, protein, topical skin actives). The thing to avoid is double-dosing any of the four components by stacking with standalone BPC-157, TB-500, GHK-Cu, or KPV — or with the sibling blends GLOW or Wolverine Stack, which overlap.

  1. Resistance training + 1.2–1.6 g/kg protein. Standard anabolic-context pairing for any tissue-repair or recovery use case. The strongest non-peptide multiplier on KLOW's repair signal.
  2. Topical GHK-Cu serum. Layered skin effect — injectable KLOW for systemic GHK-Cu gene expression plus topical for local skin concentration. Applying high-concentration vitamin C topical at the same time as topical GHK-Cu.
  3. Topical retinoids. Compatible with KLOW. The collagen-stimulating effects are additive.
  4. Conflicts: full-dose standalone components. KLOW already contains BPC-157, TB-500, GHK-Cu, and KPV at meaningful doses. Adding standalone protocols of any of these doubles the dose without independent benefit.
  5. Conflicts: GLOW and Wolverine Stack. Both overlap with KLOW's components. See GLOW for the 3-component skin/recovery version (no KPV) or Wolverine Stack for the 2-component pure-injury version (BPC-157 + TB-500 only).

What are the side effects of KLOW?

Most reported KLOW side effects are mild and local — injection-site reactions, transient fatigue, mild gastrointestinal changes — and consistent with what individual components produce in their own research. There is no controlled safety trial of the four-peptide blend, so all severity estimates are extrapolated from each component's literature plus user reports. The GHK-Cu copper-allergy risk and the BPC-157 / TB-500 anti-doping prohibitions are the most material concerns to flag.

Common (most users)

  1. Injection site reactions. Mild redness, irritation, or transient pinkness at the injection site. The most commonly reported KLOW side effect.
  2. Transient fatigue. Mild post-injection tiredness, typically resolving overnight.
  3. Mild GI changes. Mild loose stool or appetite changes — reflects BPC-157 and KPV activity on gut signaling.

Less common (moderate)

  1. Headache. Typically mild, common after first few doses during the early cycle.
  2. Lightheadedness. Usually transient and dose-related; often resolved by smaller volumes or split dosing.
  3. Skin pigmentation drift. Theoretical concern with GHK-Cu and α-MSH-derived peptides. Whether KPV binds melanocortin receptors has not been shown; mouse colitis data found its effects at least partly independent of MC1R. No human study of KPV pigmentation was found.

Serious (rare)

  1. Copper allergy reactions. From the GHK-Cu component — hives, swelling, or systemic allergic response. Reported practice stops immediately.
  2. Anti-doping prohibitions. BPC-157 is named on the 2026 WADA Prohibited List under S0 (Non-Approved Substances) and TB-500 under S2.3 (Growth Factors and Growth Factor Modulators). Both classes are prohibited at all times, and every KLOW formulation contains both.
  3. Theoretical component-level concerns apply. Each component carries its own (mostly preclinical) safety considerations — see the individual component pages.

KLOW combines four peptides with no FDA approval as injectables. Compounded preparations vary widely in quality — third-party HPLC testing of each component is essential. The combined safety profile of the four-peptide blend has not been formally studied.

Common question: What are the side effects of the KLOW peptide blend?

Does KLOW interact with other drugs?

KLOW has no well-documented systemic drug interactions. Each component's individual interaction profile applies — BPC-157 and TB-500's angiogenic activity creates a theoretical concern for users on anticoagulants, and GHK-Cu's copper component creates theoretical concern for users on copper-modifying agents or vitamin C megadosing. None of these have shown up as clinically meaningful in the component literature.

  1. Anticoagulants (warfarin, DOACs). Theoretical concern from BPC-157 and TB-500 angiogenic activity. No documented clinical events.
  2. High-concentration topical vitamin C. Reported applied at separate times from topical GHK-Cu products when combining injectable KLOW with topical regimens.
  3. Copper-modifying agents. Theoretical concern from the GHK-Cu component for users on zinc supplementation at high doses or on copper-chelating therapy.
  4. Component-level interactions. Cross-reference individual component pages — BPC-157, TB-500, GHK-Cu, KPV — for full per-component interaction profiles.
  5. Alcohol. No specific interaction documented. General hydration concerns apply for any peptide-injection protocol.

How should KLOW be stored?

  1. Lyophilized (powder) form: -20°C long-term, 2–8°C short-term (refrigerated).
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade BPC-157, TB-500, GHK-Cu, or KPV remains stable — this page does not state a duration as fact.
  3. Reconstitution: bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. The reconstituted solution is not frozen. Freezing damages the peptides and renders them inactive.
  5. KLOW is stored protected from light, in the original container or an amber vial.
  6. Discard if the solution is cloudy, discolored, or contains particles.

What are the limitations of KLOW research?

KLOW is a community-derived blend — no controlled trial has tested the four-peptide combination as a single product. All efficacy and safety claims rest on each component's independent literature plus mechanistic reasoning about complementarity. The regulatory status is the strictest concern: none of the four components are FDA-approved as injectables, and quality varies dramatically across vendors.

KLOW is NOT FDA-approved. Each individual component has its own regulatory status — GHK-Cu (injectable: nominated-but-withdrawn on FDA’s list, previously Category 2; non-injectable: 503A Category 1, not approved), BPC-157 (nominated-but-withdrawn, previously Category 2; not in Category 1), TB-500 (research-only), KPV (research-only, no approved injectable form). The four-peptide blend has no clinical trial evidence as a combination.

Compounded KLOW preparations are sold as “research peptides.” Quality varies dramatically by source. A third-party HPLC certificate on each component is the only check available — both for purity and to verify the labeled 50 / 10 / 10 / 10 mg breakdown.

Synergy claims are mechanistic, not empirical. The proposition that KPV-mediated NF-κB suppression amplifies the regenerative signal from BPC-157, TB-500, and GHK-Cu is biologically plausible but has not been tested as a combination versus its components or versus a 3-peptide GLOW formulation. The narrower 2-component combination of BPC-157 and TB-500 (a subset of KLOW, also sold as Wolverine Stack) has been tested directly in one 2026 rat study, which found no added benefit from combining the two versus either alone. A small, uncontrolled knee-injection chart review gave 4 patients BPC-157 plus full-length thymosin beta-4 (not TB-500): 3 of 4 improved, versus 11 of 12 on BPC-157 alone. It was not randomised and did not test the blend. Neither result supports KLOW's combination rationale for those two components.

Anti-doping: on the 2026 WADA Prohibited List, BPC-157 is named under S0 (Non-Approved Substances) and TB-500 under S2.3 (Growth Factors and Growth Factor Modulators, as a thymosin-β4 derivative); both classes are prohibited at all times. GHK-Cu and KPV are not named on that list, though every class is written “including, but not limited to”, so absence from the text is not a ruling that either is permitted. Every KLOW formulation contains BPC-157 and TB-500.

KLOW FAQ

What is KLOW?

KLOW is a research-grade 4-component peptide blend: BPC-157 + TB-500 + GHK-Cu + KPV. It extends the GLOW blend (BPC-157 + TB-500 + GHK-Cu) by adding KPV, a tripeptide derived from α-melanocyte-stimulating hormone (α-MSH). The standard vendor SKU is an 80 mg vial: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV.

How does KLOW differ from GLOW?

KLOW is GLOW plus KPV. The GLOW combination already covers tissue repair (BPC-157 + TB-500) and skin/collagen remodeling (GHK-Cu). KLOW adds an anti-inflammatory layer through KPV, which inhibits NF-κB and dampens the inflammatory environment that can interfere with the rebuilding signals from the other three components. Researchers typically step up: Wolverine Stack (pure injury recovery) → GLOW (recovery + skin) → KLOW (recovery + skin + inflammation control).

How does KPV work in the blend?

KPV is a lysine–proline–valine tripeptide derived from the C-terminal end of α-MSH. It enters cells via the PepT1 nutrient transporter and inhibits the NF-κB inflammatory signaling pathway, reducing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in cell and mouse studies. In mouse colitis its effects were at least partly independent of the MC1R melanocortin receptor (Kannengiesser 2008); whether KPV binds melanocortin receptors has not been shown. In a multi-component blend, this is meant to pre-empt the inflammatory cascade so the regenerative signals from BPC-157, TB-500, and GHK-Cu can act on a calmer tissue environment.

Is KLOW FDA-approved?

No. None of the four components are FDA-approved as injectables. On FDA’s compounding lists (current as of April 22, 2026), injectable GHK-Cu, previously in Category 2, is on FDA’s list of substances “nominated but withdrawn”, and non-injectable GHK-Cu sits in 503A Category 1 (under evaluation, not approved); BPC-157, previously in Category 2, is also on the withdrawn list and not in Category 1; TB-500 and KPV have no FDA approval. There are no clinical trials of the KLOW combination — synergy claims rest on the mechanistic complementarity of each component, not on a comparative trial of the blend.

What's a typical KLOW dose?

Vendor protocols converge on 0.1 mL (10 units on a U-100 insulin syringe) once daily subcutaneously for the standard 80 mg vial reconstituted with 2 mL bacteriostatic water. That delivers approximately 4 mg total per dose: 2.5 mg GHK-Cu + 0.5 mg BPC-157 + 0.5 mg TB-500 + 0.5 mg KPV. Skincare-focused protocols sometimes use 2.5 mL BAC water (anchored to a 2 mg GHK-Cu target dose); injury-focused protocols anchor to 0.5 mg BPC-157 and use 2 mL. Standard cycle: 8–12 weeks active, then a 4-week break.

Where can I buy KLOW?

KLOW is sold as a pre-blended 80 mg vial by specialty research peptide vendors. Quality varies dramatically by source — third-party HPLC testing of each component is essential. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

Can KLOW be stacked with other peptides?

KLOW already contains the full BPC-157 + TB-500 + GHK-Cu + KPV set, so stacking with standalone versions of any of those four components risks double-dosing. The most common additions are resistance training and adequate protein for anabolic context, and topical GHK-Cu serum for layered skin effect. Avoid stacking with full-dose GLOW or Wolverine Stack — they overlap with KLOW's components.

Is the blend's safety profile established?

Not as a combination, and evidence depth varies sharply by component. BPC-157 has three small, uncontrolled human papers by the same lead author (knee injections, n=17; bladder injections for interstitial cystitis, n=12; IV safety, n=2), none subcutaneous, plus animal data. TB-500 has animal data only; no human study of TB-500 was found. GHK-Cu has human evidence only for the topical route, none for injection; KPV has animal colitis data only, no human trial. The one direct BPC-157 + TB-500 combination study, a 2026 rat study, found no added benefit over either peptide alone. In the uncontrolled knee paper, 3 of 4 patients given BPC-157 plus full-length thymosin beta-4 (not TB-500) improved, versus 11 of 12 given BPC-157 alone; it was not randomised and did not test the blend. Most observed side effects in user reports are mild (injection site reactions, transient fatigue, mild GI changes) and consistent with what individual components produce, but the four-peptide blend itself has no safety trial.

References

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
  3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: A Multi-Functional Regenerative Peptide. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
  4. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-5. https://pmc.ncbi.nlm.nih.gov/articles/PMC2095288/
  5. Kelly JM, Moir AJ, Carlson K, et al. Immobilized α-melanocyte stimulating hormone 10–13 (GKPV) inhibits tumor necrosis factor-α stimulated NF-κB activity. Peptides. 2006;27(2):431-437. https://www.sciencedirect.com/science/article/abs/pii/S0196978105004560
  6. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: Actin Sequestering Protein Moonlights to Repair Injured Tissues. Trends Mol Med. 2005;11(9):421-9. https://pubmed.ncbi.nlm.nih.gov/16099219/
  7. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. https://pubmed.ncbi.nlm.nih.gov/42542926/
  8. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/

Published Studies

KLOW has no controlled trial as a combination. The studies below are the key peer-reviewed sources for each individual component's mechanism — the empirical basis for the four-peptide blend's mechanistic rationale.

International Journal of Molecular Sciences · 2018Open Access
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data →

Pickart L, Margolina A

Comprehensive review reporting, from Broad Institute Connectivity Map data in cancer cell lines, that GHK shifts expression of over 4,000 human genes, including genes associated with skin aging, wound healing, and tissue regeneration. The gene figure is a database analysis by the compound's discoverer, not a primary human study. The paper synthesizes decades of work demonstrating GHK-Cu's roles in collagen and elastin synthesis, copper transport, anti-inflammatory signaling, and stem-cell support. It is the foundational reference for GHK-Cu's contribution to combination blends like KLOW.

Journal of Molecular Medicine · 2017Paywalled
Therapeutic Potential of Pro-Angiogenic BPC157 is Associated with VEGFR2 Activation and Up-Regulation →

Hsieh MJ, Liu HT, Wang CN, et al.

Shows BPC-157's mechanism centered on the nitric oxide / VEGFR2 / FAK-paxillin axis — driving angiogenesis, endothelial protection, and rapid vascular network reconstruction at injury sites. BPC-157's vascular action is the primary mechanism by which it complements TB-500's cellular-migration effect in tissue-repair blends like Wolverine, GLOW, and KLOW.

Expert Opinion on Biological Therapy · 2012Paywalled
Thymosin β4: a Multi-Functional Regenerative Peptide →

Goldstein AL, Hannappel E, Sosne G, Kleinman HK

Reviews the parent peptide of TB-500 (the active fragment of thymosin β4). Mechanism centers on G-actin sequestration to enable cytoskeletal remodeling, cellular migration of repair cells (fibroblasts, endothelial progenitors) to injury sites, and the anti-fibrotic Ac-SDKP fragment that biases healing toward functional tissue rather than scar. In KLOW, TB-500 supplies the cellular-migration arm of the repair triad.

Annals of the Rheumatic Diseases · 2007Open Access
α-MSH-Related Peptides: A New Class of Anti-Inflammatory and Immunomodulating Drugs →

Luger TA, Brzoska T

Comprehensive review of α-MSH and its C-terminal tripeptide KPV as anti-inflammatory agents. Establishes that most of α-MSH's anti-inflammatory activity is recapitulated by KPV alone — including suppression of pro-inflammatory cytokines, inhibition of NF-κB nuclear translocation, and modulation of adhesion molecule expression — which is the rationale vendors give for using KPV rather than α-MSH itself in blends like KLOW.

Peptides / ScienceDirect · 2006Paywalled
α-MSH (10–13) Inhibits TNF-α-Stimulated NF-κB Activity →

Kelly JM, Moir AJ, Carlson K, et al.

Cell study showing that the α-MSH 10–13 fragment GKPV (which includes KPV), soluble or bead-immobilized, inhibits TNF-α-stimulated NF-κB activity in vitro. The authors state it was not known whether these peptides act via MC1R; their data suggest a cell receptor-based mechanism. It does not show that KPV acts without melanocortin receptors.

RecoveryTissue RepairSkin HealthAnti-InflammatoryCombination BlendPreclinical

Related Peptides

BPC-157TB-500GHK-CuKPV

Related Blends

Wolverine StackGLOW

We may earn commissions from peptide vendor affiliate links.

Have a question about KLOW? Send us an email